How to effectively reverse life-thretening effects of non-vitamin K oral anticoagulants?
For several decades the vitamin K antagonist oral anticoagulants were the only outpatient therapy that existed to reduce the risk of stroke and thromboembolism until non-vitamin K oral anticoagulants (NOACs). Direct thrombin inhibitor: dabigatran and factor Xa inhibitors: apixaban, rivaroxaban, and...
Saved in:
Main Authors: | Łukasz Wołowiec (Author), Joanna Banach (Author), Daniel Rogowicz (Author), Magdalena Węglarz (Author), Walery Zukow (Author), Władysław Sinkiewicz (Author) |
---|---|
Format: | Book |
Published: |
Kazimierz Wielki University,
2017-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
How to effectively reverse life-thretening effects of non-vitamin K oral anticoagulants?
by: Łukasz Wołowiec, et al.
Published: (2017) -
Inhibitory proproteinowej konwertazy subtylizyny/keksyny 9 nowym, przełomowym narzędziem terapeutycznym w leczeniu dyslipidemii = Proprotein convertase subtilisin/kexin type 9 inhibitors are a new, groundbreaking therapeutic tool in the treatment of dyslipidemia
by: Łukasz Wołowiec, et al.
Published: (2016) -
Inhibitory proproteinowej konwertazy subtylizyny/keksyny 9 nowym, przełomowym narzędziem terapeutycznym w leczeniu dyslipidemii = Proprotein convertase subtilisin/kexin type 9 inhibitors are a new, groundbreaking therapeutic tool in the treatment of dyslipidemia
by: Łukasz Wołowiec, et al.
Published: (2016) -
Non-vitamin K oral anticoagulant in the prevention and treatment of venous thromboembolism. Why betrixaban is different?
by: Łukasz Wołowiec, et al.
Published: (2017) -
Non-vitamin K oral anticoagulant in the prevention and treatment of venous thromboembolism. Why betrixaban is different?
by: Łukasz Wołowiec, et al.
Published: (2017)